Jacques Izopet

Jacques Izopet's AcademicInfluence.com Rankings

Jacques Izopet

Philosophy

#5886

World Rank

#8812

Historical Rank

Logic

#3095

World Rank

#4205

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Jacques Izopet's Degrees

PhD Microbiology Université Paris Cité
Masters Molecular Biology Federal University of Toulouse Midi-Pyrénées

Why Is Jacques Izopet Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Jacques Izopet's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Hepatitis E virus and chronic hepatitis in organ-transplant recipients. (2008) (1163)
Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients (2021) (588)
Factors associated with chronic hepatitis in patients with hepatitis E virus infection who have received solid organ transplants. (2011) (553)
Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment (2006) (487)
Ribavirin for chronic hepatitis E virus infection in transplant recipients. (2014) (410)
Zika virus: high infectious viral load in semen, a new sexually transmitted pathogen? (2016) (359)
Hepatitis E Virus Antibodies in Blood Donors, France (2011) (350)
Proposed reference sequences for hepatitis E virus subtypes. (2016) (338)
Hepatitis E Virus Infection (2014) (304)
Hepatitis E Virus and Neurologic Disorders (2011) (284)
Ribavirin therapy inhibits viral replication on patients with chronic hepatitis e virus infection. (2010) (274)
Hepatitis E virus infection (2017) (261)
Fulminant liver failure from acute autochthonous hepatitis E in France: description of seven patients with acute hepatitis E and encephalopathy (2007) (249)
Hepatitis E in the south west of France in individuals who have never visited an endemic area (2004) (248)
Hepatitis E Virus Strains in Rabbits and Evidence of a Closely Related Strain in Humans, France (2012) (225)
Genes of the major histocompatibility complex class II influence the outcome of hepatitis C virus infection. (1997) (225)
Influence of Immunosuppressive Therapy on the Natural History of Genotype 3 Hepatitis-E Virus Infection After Organ Transplantation (2010) (207)
Hepatitis E Virus‐Related Cirrhosis in Kidney‐and Kidney–Pancreas‐Transplant Recipients (2008) (206)
Treatment of chronic hepatitis C with recombinant interferon alpha in kidney transplant recipients. (1995) (196)
Hepatitis E virus infection as a cause of graft hepatitis in liver transplant recipients (2010) (192)
High prevalence of anti‐hepatitis E virus antibodies in blood donors from South West France (2008) (191)
Evidence that clearance of hepatitis C virus RNA after alpha-interferon therapy in dialysis patients is sustained after renal transplantation. (2003) (189)
A nationwide survey of hepatitis E viral infection in French blood donors (2016) (187)
Efficacy and Safety of Sofosbuvir‐Based Antiviral Therapy to Treat Hepatitis C Virus Infection After Kidney Transplantation (2016) (187)
Pegylated interferon-alpha for treating chronic hepatitis E virus infection after liver transplantation. (2010) (184)
Characteristics of autochthonous hepatitis E virus infection in solid-organ transplant recipients in France. (2010) (178)
Hepatitis E Virus and the Kidney in Solid-Organ Transplant Patients (2012) (175)
Determining hepatitis C genotype by analyzing the sequence of the NS5b region. (2003) (175)
Geographical and temporal distribution of SARS-CoV-2 clades in the WHO European Region, January to June 2020 (2020) (163)
Altered CD4+ T cell homing to the gut impairs mucosal immune reconstitution in treated HIV-infected individuals. (2012) (160)
Changing of hepatitis C virus genotype patterns in France at the beginning of the third millenium: The GEMHEP GenoCII Study (2005) (159)
Pharmacokinetics of alphaIFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: clinical implications. (1998) (156)
Zika virus in semen and spermatozoa. (2016) (154)
Hepatitis E (2012) (153)
Hepatitis E Virus Genotype 3 Diversity, France (2009) (152)
Update: proposed reference sequences for subtypes of hepatitis E virus (species Orthohepevirus A) (2020) (151)
ZIKA virus reveals broad tissue and cell tropism during the first trimester of pregnancy (2016) (151)
Insertions and Duplications in the Polyproline Region of the Hepatitis E Virus (2020) (146)
Sequence analysis of the NS5A protein of European hepatitis C virus 1b isolates and relation to interferon sensitivity. (1998) (144)
French National Sentinel Survey of Antiretroviral Drug Resistance in Patients With HIV-1 Primary Infection and in Antiretroviral-Naive Chronically Infected Patients in 2001-2002 (2005) (142)
Hepatitis C virus genotypes in France: relationship with epidemiology, pathogenicity and response to interferon therapy (1999) (140)
Hepatitis E Virus Infection without Reactivation in Solid-Organ Transplant Recipients, France (2011) (139)
Changes in Human Immunodeficiency Virus Type 1 Populations after Treatment Interruption in Patients Failing Antiretroviral Therapy (2001) (138)
Correlation between genotypic predictions based on V3 sequences and phenotypic determination of HIV-1 tropism (2008) (138)
HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial (1997) (137)
Acute hepatitis E in south-west France over a 5-year period. (2009) (132)
Rabbit Hepatitis E Virus Infections in Humans, France (2017) (132)
Hepatitis E Virus Seroprevalence and Chronic Infections in Patients with HIV, Switzerland (2011) (131)
Hepatitis E virus reinfections in solid-organ-transplant recipients can evolve into chronic infections. (2014) (131)
Mutations of hepatitis C virus 1b NS5A 2209-2248 amino acid sequence do not predict the response to recombinant interferon-alfa therapy in French patients. (1997) (129)
HIV-1 Residual Viremia Correlates with Persistent T-Cell Activation in Poor Immunological Responders to Combination Antiretroviral Therapy (2009) (128)
Stable prevalence of genotypic drug resistance mutations but increase in non-B virus among patients with primary HIV-1 infection in France (2003) (126)
New Natural Intergenotypic (2/5) Recombinant of Hepatitis C Virus (2007) (122)
Hepatitis E Virus Infections in Blood Donors, France (2014) (122)
R5 to X4 Switch of the Predominant HIV-1 Population in Cellular Reservoirs During Effective Highly Active Antiretroviral Therapy (2005) (121)
Emergence of zidovudine and multidrug-resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus didanosine combination therapy. STADI Group. (1999) (118)
Genotype 3 Diversity and Quantification of Hepatitis E Virus RNA (2011) (117)
How Should Hepatitis E Virus Infection Be Defined in Organ‐Transplant Recipients? (2013) (114)
Hepatitis E virus excretion can be prolonged in patients with hematological malignancies. (2010) (113)
A national survey of acute hepatitis E in France (2008) (112)
Natural History of Hepatitis C Virus‐Related Liver Fibrosis After Renal Transplantation (2005) (111)
Study of hepatitis E virus infection of genotype 1 and 3 in mice with humanised liver (2016) (108)
Simultaneous detection of gastrointestinal pathogens with a multiplex Luminex-based molecular assay in stool samples from diarrhoeic patients. (2013) (107)
A Large Nosocomial Outbreak of Hepatitis C Virus Infections at a Hemodialysis Center (2005) (107)
Comparison of Hepatitis C Virus NS5b and 5′ Noncoding Gene Sequencing Methods in a Multicenter Study (2005) (105)
Efficiency of a boost with a third dose of anti-SARS-CoV-2 messenger RNA-based vaccines in solid organ transplant recipients (2021) (103)
HIV-1 subtyping using phylogenetic analysis of pol gene sequences. (2001) (102)
Long-term impact of renal transplantation on liver fibrosis during hepatitis C virus infection. (2002) (100)
Three-month pegylated interferon-alpha-2a therapy for chronic hepatitis E virus infection in a haemodialysis patient. (2010) (100)
Sperm washing and virus nucleic acid detection to reduce HIV and hepatitis C virus transmission in serodiscordant couples wishing to have children (2000) (99)
Performance of anti-HEV assays for diagnosing acute hepatitis E in immunocompromised patients. (2013) (99)
Safety and Immunogenicity of Anti–SARS-CoV-2 Messenger RNA Vaccines in Recipients of Solid Organ Transplants (2021) (98)
Acute autochthonous hepatitis E in western patients with underlying chronic liver disease: a role for ribavirin? (2011) (96)
Zika Virus Infection and Prolonged Viremia in Whole-Blood Specimens (2017) (95)
High Rate of Hepatitis C Virus Clearance in Hemodialysis Patients after Interferon-α Therapy (1997) (95)
Automated Extraction and Quantification of Human Cytomegalovirus DNA in Whole Blood by Real-Time PCR Assay (2003) (94)
Hepatitis E Virus Quasispecies and the Outcome of Acute Hepatitis E in Solid-Organ Transplant Patients (2012) (94)
High Proportion of Asymptomatic Infections in an Outbreak of Hepatitis E Associated With a Spit-Roasted Piglet, France, 2013. (2016) (93)
Characterization of the lipid envelope of exosome encapsulated HEV particles protected from the immune response. (2017) (92)
Hepatitis E Virus Infection in Immunosuppressed Patients: Natural History and Therapy (2013) (92)
Shift in HIV resistance genotype after treatment interruption and short-term antiviral effect following a new salvage regimen (2000) (92)
Molecular evidence for nosocomial transmission of hepatitis C virus in a French hemodialysis unit. (1999) (91)
Extrahepatic manifestations of hepatitis E virus (2016) (91)
Hepatitis E Virus Lifecycle and Identification of 3 Forms of the ORF2 Capsid Protein. (2018) (90)
Longitudinal analysis of hepatitis C virus replication and liver fibrosis progression in renal transplant recipients. (2000) (90)
Transmissions of hepatitis C virus during the ancillary procedures for assisted conception. (2000) (90)
Poor Anti-SARS-CoV-2 Humoral and T-cell Responses After 2 Injections of mRNA Vaccine in Kidney Transplant Recipients Treated with Belatacept. (2021) (90)
Factors of intermittent HIV-1 excretion in semen and efficiency of sperm processing in obtaining spermatozoa without HIV-1 genomes (2004) (90)
Analytical evaluation of HCV core antigen and interest for HCV screening in haemodialysis patients. (2010) (89)
Hepatitis C virus infection in French hemodialysis units: A multicenter study (2000) (89)
Population-Based Sequencing of the V3 Region of env for Predicting the Coreceptor Usage of Human Immunodeficiency Virus Type 1 Quasispecies (2007) (88)
Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996–2006 in France (2009) (88)
Prolonged hepatitis E in an immunocompromised patient (2006) (87)
The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): Early findings, 2006-2010 (2010) (87)
CXCR4-using viruses in plasma and peripheral blood mononuclear cells during primary HIV-1 infection and impact on disease progression (2010) (87)
Multicenter evaluating of a commercially available PCR assay for diagnosing enterovirus infection in a panel of cerebrospinal fluid specimens (1996) (87)
HCV/HIV co-infection, HCV viral load and mode of delivery: risk factors for mother-to-child transmission of hepatitis C virus? (2007) (86)
Study of host- and virus-related factors associated with spontaneous hepatitis C virus clearance. (2000) (86)
Good Performance of Immunoglobulin M Assays in Diagnosing Genotype 3 Hepatitis E Virus Infections (2009) (85)
Persistence of distinct HIV-1 populations in blood monocytes and naive and memory CD4 T cells during prolonged suppressive HAART (2005) (85)
Monitoring human enteric viruses in wastewater and relevance to infections encountered in the clinical setting: a one-year experiment in central France, 2014 to 2015 (2018) (84)
Hepatitis E: An emerging infection in high income countries. (2014) (84)
Ribavirin pharmacokinetics in renal and liver transplant patients: evidence that it depends on renal function. (2004) (84)
New NS5B polymerase inhibitors for hepatitis C (2010) (84)
Long-term ribavirin therapy in hepatitis C virus-positive renal transplant patients: effects on renal function and liver histology. (2003) (83)
Zika virus in semen of a patient returning from a non-epidemic area. (2016) (83)
Changes in hepatitis C virus RNA viremia concentrations in long-term renal transplant patients after introduction of mycophenolate mofetil. (2000) (83)
Evaluation of the Genotypic Prediction of HIV-1 Coreceptor Use versus a Phenotypic Assay and Correlation with the Virological Response to Maraviroc: the ANRS GenoTropism Study (2010) (82)
High immunogenicity of a messenger RNA based vaccine against SARS-CoV-2 in chronic dialysis patients (2021) (82)
Hepatitis E virus in patients with decompensated chronic liver disease: a prospective UK/French study (2015) (80)
TaqMan amplification system with an internal positive control for HCV RNA quantitation. (2004) (80)
Heterogeneity of hepatitis C virus genotype 4 strains circulating in south-western France. (2005) (79)
Incidence of HCV infection in French hemodialysis units: A prospective study (2005) (79)
Antibody titers and protection against a SARS-CoV-2 infection (2021) (78)
Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine (1999) (78)
Development and performance of a new recombinant virus phenotypic entry assay to determine HIV-1 coreceptor usage. (2010) (77)
Hepatitis C virus infection among dialysis patients in Tunisia: Incidence and molecular evidence for nosocomial transmission (2006) (77)
Prevalence of drug resistant mutants and virological response to combination therapy in patients with primary HIV‐1 infection (2000) (77)
Hepatitis E Pathogenesis (2016) (77)
Hepatitis C virus-related kidney disease: an overview. (2008) (76)
Genotypic and Phenotypic Resistance Patterns of Human Immunodeficiency Virus Type 1 Variants with Insertions or Deletions in the Reverse Transcriptase (RT): Multicenter Study of Patients Treated with RT Inhibitors (2001) (76)
Hepatitis E virus: chronic infection, extra-hepatic manifestations, and treatment. (2015) (76)
Assessment of 4 Doses of SARS-CoV-2 Messenger RNA–Based Vaccine in Recipients of a Solid Organ Transplant (2021) (76)
Increasing prevalence of transmitted drug resistance mutations and non-B subtype circulation in antiretroviral-naive chronically HIV-infected patients from 2001 to 2006/2007 in France. (2010) (73)
Genotype specific pathogenicity of hepatitis E virus at the human maternal-fetal interface (2018) (73)
Chronic hepatitis E virus infection: successful virologic response to pegylated interferon-alpha therapy. (2010) (73)
Treatment of hepatitis C virus infection (HCV) after renal transplantation: implications for HCV-positive dialysis patients awaiting a kidney transplant. (2006) (73)
Quantitation of human cytomegalovirus in recipients of solid organ transplants by real‐time quantitative PCR and pp65 antigenemia (2003) (70)
Entecavir Therapy for Adefovir-Resistant Hepatitis B Virus Infection in Kidney and Liver Allograft Recipients (2008) (68)
Decreased prevalence and incidence of HCV markers in haemodialysis units: a multicentric French survey. (2011) (67)
Executive summary of the 2018 KDIGO Hepatitis C in CKD Guideline: welcoming advances in evaluation and management. (2018) (67)
Early assessment of diffusion and possible expansion of SARS-CoV-2 Lineage 20I/501Y.V1 (B.1.1.7, variant of concern 202012/01) in France, January to March 2021 (2021) (67)
Hepatitis C virus and kidney disease. (2013) (66)
Seroprevalence in blood donors reveals widespread, multi-source exposure to hepatitis E virus, southern France, October 2011. (2015) (65)
Intermittent detection of hepatitis C virus (HCV) in semen from men with human immunodeficiency virus type 1 (HIV-1) and HCV. (2003) (65)
Clinical phenotype and outcome of hepatitis E virus–associated neuralgic amyotrophy (2017) (64)
High rate of hepatitis C virus infection and predominance of genotype 4 among elderly inhabitants of a remote village of the rain forest of South Cameroon (2003) (64)
COVID-19, Virology and Geroscience: A Perspective (2020) (64)
Intermittent antiretroviral therapy in patients with controlled HIV infection. (2007) (64)
Mutation in the Hepatitis E Virus Polymerase and Outcome of Ribavirin Therapy (2015) (63)
Hepatitis E virus infection and acute non-traumatic neurological injury: A prospective multicentre study. (2017) (63)
Prediction of HIV Type 1 Subtype C Tropism by Genotypic Algorithms Built From Subtype B Viruses (2010) (63)
Prevalence of HIV-1 Drug Resistance in Treated Patients: A French Nationwide Study (2007) (63)
No evidence of occult hepatitis C virus (HCV) infection in serum of HCV antibody‐positive HCV RNA‐negative kidney‐transplant patients (2009) (63)
High sensitivity of specific genotypic tools for detection of X4 variants in antiretroviral-experienced patients suitable to be treated with CCR5 antagonists (2010) (62)
Molecular Evidence for Mother-to-Child Transmission of Multiple Variants by Analysis of RNA and DNA Sequences of Human Immunodeficiency Virus Type 1 (1998) (62)
Hepatitis E Virus: What Transplant Physicians Should Know (2012) (61)
Liver histology in patients with sporadic acute hepatitis E: a study of 11 patients from South-West France (2007) (61)
Influence of the HCV subtype on the virological response to pegylated interferon and ribavirin therapy (2009) (61)
Severe thrombocytopenia associated with acute autochthonous hepatitis E. (2010) (61)
Virological and Pharmacological Parameters Predicting the Response to Lopinavir-Ritonavir in Heavily Protease Inhibitor-Experienced Patients (2005) (61)
An Early Viral Response Predicts the Virological Response to Ribavirin in Hepatitis E Virus Organ Transplant Patients (2015) (60)
Protracted fecal shedding of HEV during ribavirin therapy predicts treatment relapse. (2015) (60)
Variability and pathogenicity of hepatitis E virus genotype 3 variants (2015) (59)
Chronic hepatitis e virus infection and treatment. (2013) (59)
Naïve T-Cell Depletion Related to Infection by X4 Human Immunodeficiency Virus Type 1 in Poor Immunological Responders to Highly Active Antiretroviral Therapy (2006) (59)
Distribution and heterogeneity of hepatitis C genotypes in hepatitis patients in Cameroon (2005) (59)
Acute hepatitis and renal function impairment related to infection by hepatitis E virus in a renal allograft recipient. (2005) (59)
Genetic Heterogeneity of Hypervariable Region 1 of the Hepatitis C Virus (HCV) Genome and Sensitivity of HCV to Alpha Interferon Therapy (2000) (58)
Definitive Clearance of a Chronic Hepatitis E Virus Infection With Ribavirin Treatment (2011) (58)
Maintenance therapy with gradual reduction of the interferon dose over one year improves histological response in patients with chronic hepatitis C with biochemical response: results of a randomized trial. (2001) (57)
Ribavirin for Hepatitis E Virus Infection After Organ Transplantation: A Large European Retrospective Multicenter Study. (2019) (57)
Treatment of autochthonous acute hepatitis E with short‐term ribavirin: a multicenter retrospective study (2016) (56)
Pegylated interferon and ribavirin therapy for chronic hepatitis C virus genotype 4 infection (2005) (56)
Repeated HIV‐1 resistance genotyping external quality assessments improve virology laboratory performance (2006) (55)
Hepatitis C virus infection among pregnant women in Yaounde, Cameroon: Prevalence, viremia, and genotypes (2003) (55)
Molecular evidence of patient-to-patient transmission of hepatitis E virus in a hematology ward. (2009) (55)
An Analysis of the Benefit of Using HEV Genotype 3 Antigens in Detecting Anti-HEV IgG in a European Population (2013) (55)
Hepatitis E is an autochthonous disease in industrialized countries. Analysis of 23 patients in South-West France over a 13-month period and comparison with hepatitis A. (2006) (55)
NS3 Protease Polymorphism and Natural Resistance to Protease Inhibitors in French Patients Infected with HCV Genotypes 1–5 (2011) (55)
Transmission and Epidemiology of Hepatitis E Virus Genotype 3 and 4 Infections. (2018) (55)
National sentinel surveillance of transmitted drug resistance in antiretroviral-naive chronically HIV-infected patients in France over a decade: 2001-2011. (2013) (54)
High rate of hepatitis C virus clearance in hemodialysis patients after interferon-alpha therapy. (1997) (54)
Influence of Polyproline Region and Macro Domain Genetic Heterogeneity on HEV Persistence in Immunocompromised Patients (2013) (54)
Low risk of hepatitis E virus reactivation after haematopoietic stem cell transplantation. (2012) (54)
Risk of zoonotic transmission of HEV from rabbits (2013) (53)
Evolution of human immunodeficiency virus type 1 populations after resumption of therapy following treatment interruption and shift in resistance genotype. (2002) (53)
Tipranavir-Ritonavir Genotypic Resistance Score in Protease Inhibitor-Experienced Patients (2008) (52)
Increased Incidence of Indinavir Nephrolithiasis in Patients with Hepatitis B or C Virus Infection (2000) (52)
Clinical Manifestations, Pathogenesis and Treatment of Hepatitis E Virus Infections (2020) (52)
Characterization of the Polyproline Region of the Hepatitis E Virus in Immunocompromised Patients (2014) (52)
Genotypic Prediction of Human Immunodeficiency Virus Type 1 CRF02-AG Tropism (2009) (52)
A pharmacokinetic model for alpha interferon administered subcutaneously. (1999) (51)
Performance of Two Commercial Assays for Detecting Hepatitis E Virus RNA in Acute or Chronic Infections (2013) (51)
Neurologic Disorders in Immunocompetent Patients with Autochthonous Acute Hepatitis E (2015) (51)
Concordance between Two Phenotypic Assays and Ultradeep Pyrosequencing for Determining HIV-1 Tropism (2011) (50)
Immunologically Silent Autochthonous Acute Hepatitis E Virus Infection in France (2004) (50)
Saliva sampling for diagnosing SARS-CoV-2 infections in symptomatic patients and asymptomatic carriers (2020) (49)
Hepatitis C Virus Genotype 5: Epidemiological Characteristics and Sensitivity to Combination Therapy with Interferon-α plus Ribavirin (2004) (49)
HIV RNA and HIV DNA in peripheral blood mononuclear cells are consistent markers for estimating viral load in patients undergoing long-term potent treatment. (2000) (49)
Hepatitis E virus seroprevalence in three hyperendemic areas: Nepal, Bangladesh and southwest France. (2015) (49)
HIV-1 Tat Protein Induces Production of Proinflammatory Cytokines by Human Dendritic Cells and Monocytes/Macrophages through Engagement of TLR4-MD2-CD14 Complex and Activation of NF-κB Pathway (2015) (49)
Baseline level and early suppression of serum HCV RNA for predicting sustained complete response to alpha‐interferon therapy (1998) (48)
HIV-1 Tat Protein Induces PD-L1 (B7-H1) Expression on Dendritic Cells through Tumor Necrosis Factor Alpha- and Toll-Like Receptor 4-Mediated Mechanisms (2014) (47)
Lopinavir/ritonavir monotherapy versus current treatment continuation for maintenance therapy of HIV-1 infection: the KALESOLO trial. (2010) (47)
Genotypic prediction of HIV-1 subtype D tropism (2011) (47)
Successful treatment of hepatitis E virus‐associated cryoglobulinemic membranoproliferative glomerulonephritis with ribavirin (2015) (47)
Ribavirin for chronic hepatitis E virus infection. (2014) (46)
Hepatitis E virus replication in human intestinal cells (2019) (46)
The use of a multiplex real-time PCR assay for diagnosing acute respiratory viral infections in children attending an emergency unit (2014) (46)
Prevalence of resistance mutations in antiretroviral-naive chronically HIV-infected patients in 1998: a French nationwide study (2001) (46)
Hepatitis E Virus-Induced Cryoglobulinemic Glomerulonephritis in a Nonimmunocompromised Person. (2016) (46)
Hepatitis E in developed countries: current status and future perspectives. (2014) (46)
Antibody titers and breakthrough infections with Omicron SARS-CoV-2 (2022) (46)
Low risk of mother-to-child transmission of hepatitis C virus in Yaounde, Cameroon: the ANRS 1262 study. (2005) (44)
Analytical sensitivity of four HIV combined antigen/antibody assays using the p24 WHO standard. (2011) (44)
Better efficacy of a 12‐month interferon alfa‐2b retreatment in patients with chronic hepatitis C relapsing after a 6‐month treatment: A multicenter, controlled, randomized trial (1998) (44)
Decay of HIV-1 DNA in patients receiving suppressive antiretroviral therapy. (1998) (44)
Outcome of Hepatitis E Virus Infection in Patients With Inflammatory Arthritides Treated With Immunosuppressants (2015) (44)
Detection of Hepatitis E Virus in Sewage After an Outbreak on a French Island (2016) (44)
Tenofovir Therapy in Hepatitis B Virus-Positive Solid-Organ Transplant Recipients (2011) (43)
Mother-to-child transmission of HIV infection and CTL escape through HLA-A2-SLYNTVATL epitope sequence variation. (2001) (43)
Zidovudine Resensitization and Dual HIV-1 Resistance to Zidovudine and Lamivudine in the Delta Lamivudine Roll-Over Study (1998) (43)
Acute hepatitis E in French patients and neurological manifestations. (2018) (42)
Genotypic Determinants of the Virological Response to Tenofovir Disoproxil Fumarate in Nucleoside Reverse Transcriptase Inhibitor-Experienced Patients (2003) (42)
Stable rearrangements of the β3–β4 hairpin loop of HIV‐1 reverse transcriptase in plasma viruses from patients receiving combination therapy (1998) (42)
Does HIV-infection influence the response of chronic hepatitis C to interferon treatment? A French multicenter prospective study. French Multicenter Study Group. (2000) (41)
Performance of an antigen assay for diagnosing acute hepatitis E virus genotype 3 infection. (2016) (41)
Genotypic Prediction of HIV-1 CRF01-AE Tropism (2012) (41)
Transmission of hepatitis E virus infection to human-liver chimeric FRG mice using patient plasma. (2017) (41)
Platelets from HIV-infected individuals on antiretroviral drug therapy with poor CD4+ T cell recovery can harbor replication-competent HIV despite viral suppression (2020) (41)
Alpha-interferon therapy for chronic hepatitis C may induce acute allograft rejection in kidney transplant patients with failed allografts. (2007) (40)
Serum concentrations of ribavirin and pegylated interferon and viral responses in patients infected with HIV and HCV (2008) (40)
Impact of hepatitis C virus duration and hepatitis C virus genotypes on renal transplant patients: correlation with clinicopathological features. (1998) (40)
Low-Rate Emergence of Thymidine Analogue Mutations and Multi-Drug Resistance Mutations in the HIV-1 Reverse Transcriptase Gene in Therapy-Naive Patients Receiving Stavudine plus Lamivudine Combination Therapy (2000) (40)
Factors Associated with Virological Response to Etravirine in Nonnucleoside Reverse Transcriptase Inhibitor-Experienced HIV-1-Infected Patients (2009) (40)
Minority variants associated with resistance to HIV-1 nonnucleoside reverse transcriptase inhibitors during primary infection. (2012) (40)
Minor HIV-1 Variants with the K103N Resistance Mutation during Intermittent Efavirenz-Containing Antiretroviral Therapy and Virological Failure (2011) (39)
Study of the association between major histocompatibility complex class II genes and the response to interferon alpha in patients with chronic hepatitis C infection. (1999) (38)
Antiretroviral effect of zidovudine–didanosine combination on blood and lymph nodes (1997) (38)
Hepatitis C virus genotype 5: epidemiological characteristics and sensitivity to combination therapy with interferon-alpha plus ribavirin. (2004) (38)
Viral load kinetics of Zika virus in plasma, urine and saliva in a couple returning from Martinique, French West Indies. (2016) (37)
Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL in 2009: a French nationwide study. (2013) (37)
CCR6− regulatory T cells blunt the restoration of gut Th17 cells along the CCR6–CCL20 axis in treated HIV-1-infected individuals (2016) (36)
Assessment of a hepatitis C virus antibody assay in saliva for epidemiological studies (1998) (36)
Wildlife Reservoir for Hepatitis E Virus, Southwestern France (2015) (35)
Amantadine therapy in renal transplant patients with hepatitis C virus infection. (2004) (35)
Hepatitis E virus infections in Europe. (2019) (35)
Transfusion-Transmitted Hepatitis E Virus Infection in France. (2019) (35)
Characterization of the Specificity, Functionality, and Durability of Host T‐Cell Responses Against the Full‐Length Hepatitis E Virus (2016) (34)
Preliminary results of treatment of chronic hepatitis C with recombinant interferon alpha in renal transplant patients. (1995) (34)
Kinetics of anti-ZIKV antibodies after Zika infection using two commercial enzyme-linked immunoassays. (2018) (34)
Evaluation of the Aptima™ transcription-mediated amplification assay (Hologic®) for detecting SARS-CoV-2 in clinical specimens (2020) (34)
Treatment of HEV Infection in Patients with a Solid-Organ Transplant and Chronic Hepatitis (2016) (33)
Factors influencing peripheral blood mononuclear cell-associated HIV-1 DNA level after long-term suppressive antiretroviral therapy in 236 patients (2009) (33)
An international multicenter study on HIV-1 drug resistance testing by 454 ultra-deep pyrosequencing. (2014) (33)
Hepatitis E virus lifecycle and identification of 3 forms of the ORF2 capsid protein (2018) (33)
Reversible posterior leukoencephalopathy syndrome in hepatitis C virus-positive long-term hemodialysis patients. (2001) (32)
Determining Seminal Plasma Human Immunodeficiency Virus Type 1 Load in the Context of Efficient Highly Active Antiretroviral Therapy (2009) (32)
Diversity of hepatitis E virus genotype 3 (2018) (31)
Severe acute hepatitis E in an HIV infected patient: Successful treatment with ribavirin. (2014) (31)
Hepatitis C virus genotypes in France: relationship with epidemiology, pathogenicity and response to interferon therapy. The GEMHEP. (1999) (31)
Temporal evolution of the distribution of hepatitis E virus genotypes in Southwestern France. (2015) (31)
Analysis of CCR5, CCR2, CX3CR1, and SDF1 polymorphisms in HIV-positive treated patients: impact on response to HAART and on peripheral T lymphocyte counts. (2006) (31)
Quantification of HIV‐1 proviral DNA by a standardized colorimetric PCR‐based assay (1998) (31)
Frequency of CXCR4-using viruses in primary HIV-1 infections using ultra-deep pyrosequencing (2011) (30)
Comparison of the QUANTIPLEX HIV-1 RNA 2.0 Assay with the AMPLICOR HIV-1 MONITOR 1.0 Assay for Quantitation of Levels of Human Immunodeficiency Virus Type 1 RNA in Plasma of Patients Receiving Stavudine-Didanosine Combination Therapy (1998) (29)
The SARS-CoV-2 seroprevalence is the key factor for deconfinement in France (2020) (29)
Predictive factors for cytomegalovirus reactivation in cytomegalovirus‐seropositive kidney‐transplant patients (2008) (29)
Multicenter Quality Control for the Detection of Hepatitis C Virus RNA in Seminal Plasma Specimens (2003) (29)
Anti-SARS-CoV-2 Monoclonal Antibodies in Solid-organ Transplant Patients (2021) (28)
Epidemiological and virological characteristics of symptomatic acute hepatitis E in Greater Cairo, Egypt. (2012) (28)
Vectorial Release of Hepatitis E Virus in Polarized Human Hepatocytes (2018) (28)
Persistent differences in the antiviral effects of highly active antiretroviral therapy in the blood and male genital tract. (2008) (27)
Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL: a 2014 French nationwide study (2017) (27)
Genetic diversity of HCV genotype 2 strains in South Western France (2007) (27)
Sensitivity of 8 CE (European Community)-approved rapid disposable tests for anti-HIV antibody detection during and after seroconversion. (2010) (26)
Screening of blood from potential organ and cornea donors for viruses (2002) (26)
Factors accelerating liver fibrosis progression in renal transplant patients receiving ribavirin monotherapy for chronic hepatitis C (2005) (26)
Progesterone and a phospholipase inhibitor increase the endosomal bis(monoacylglycero)phosphate content and block HIV viral particle intercellular transmission. (2013) (26)
Influence of treatment with neutralizing monoclonal antibodies on the SARS-CoV-2 nasopharyngeal load and quasispecies (2021) (25)
HEV infection in French HIV-infected patients. (2017) (25)
Hepatitis E Virus Infection in Solid Organ Transplant Recipients, France (2017) (25)
Hepatitis E virus genotype 3 and capsid protein in the blood and urine of immunocompromised patients. (2019) (25)
Evolution of total and integrated HIV-1 DNA and change in DNA sequences in patients with sustained plasma virus suppression. (2002) (25)
Resistance mutations in SARS-CoV-2 omicron variant after tixagevimab-cilgavimab treatment (2022) (25)
Unique NS5b Hepatitis C Virus Gene Sequence Consensus Database Is Essential for Standardization of Genotype Determinations in Multicenter Epidemiological Studies (2006) (24)
Low interleukin‐10 production by monocytes of patients with a self‐limiting hepatitis C virus infection (2009) (24)
CCR5 structural plasticity shapes HIV-1 phenotypic properties (2018) (24)
Assessment of HIV-1 subtyping for Cameroon strains using phylogenetic analysis of pol gene sequences. (2003) (24)
Screening for SARS-CoV-2 antibodies among healthcare workers in a university hospital in southern France (2020) (24)
Low Frequency of CXCR4-Using Viruses in Patients at the Time of Primary Non-Subtype-B HIV-1 Infection (2010) (24)
Prospective monitoring of cytomegalovirus, Epstein-Barr virus, BK virus, and JC virus infections on belatacept therapy after a kidney transplant. (2014) (24)
Hepatitis A: Epidemiology, High-Risk Groups, Prevention and Research on Antiviral Treatment (2021) (24)
Renal side effects of adefovir in hepatitis B virus-(HBV) positive kidney allograft recipients. (2009) (24)
JC virus DNA in the peripheral blood of renal transplant patients: A 1‐year prospective follow‐up in France (2011) (24)
Using RT-PCR and bDNA assays to measure non-clade B HIV-1 subtype RNA. (1999) (23)
Minority resistant HIV-1 variants and the response to first-line NNRTI therapy. (2015) (23)
Monitoring hepatitis E virus fecal shedding to optimize ribavirin treatment duration in chronically infected transplant patients. (2019) (23)
Quantification of HEV RNA by Droplet Digital PCR (2016) (23)
Anti-SARS-CoV-2 spike protein and neutralizing antibodies at 1 and 3 months after three doses of SARS-CoV-2 vaccine in a large cohort of solid organ transplant patients (2022) (22)
Successful treatment of fibrosing cholestatic hepatitis with pegylated interferon, ribavirin and sofosbuvir after a combined kidney–liver transplantation (2015) (22)
Predictive Factors and Selection of Thymidine Analogue Mutations by Nucleoside Reverse Transcriptase Inhibitors According to Initial Regimen Received (2003) (22)
Conventional and innate lymphocytes response at the acute phase of HEV infection in transplanted patients. (2016) (22)
TLR7 dosage polymorphism shapes interferogenesis and HIV-1 acute viremia in women. (2020) (22)
Effects of long-term lamivudine therapy in renal-transplant patients. (2004) (22)
Frequent Transient Hepatitis C viremia without Seroconversion among Healthcare Workers in Cairo, Egypt (2013) (22)
Performance of the Xpert HBV Viral Load assay versus the Aptima Quant assay for quantifying hepatitis B virus DNA. (2019) (22)
Hepatitis C Virus Genotyping Using an Oligonucleotide Microarray Based on the NS5B Sequence (2010) (22)
GEMHEP multicenter quality control study of PCR detection of GB virus C/hepatitis G virus RNA in serum (1997) (22)
A cohort study of treatment-experienced HIV-1-infected patients treated with raltegravir: factors associated with virological response and mutations selected at failure. (2013) (21)
New insights into the natural history of hepatitis E virus infection through a longitudinal study of multitransfused immunocompetent patients in France (2016) (21)
No Reactivation of Hepatitis E Virus After Kidney Retransplantation (2012) (21)
Phenotyping methods for determining HIV tropism and applications in clinical settings (2012) (21)
Four-days-a-week antiretroviral maintenance therapy in virologically controlled HIV-1-infected adults: the ANRS 162-4D trial (2018) (21)
Comparison of 2 highly automated nucleic acid extraction systems for quantitation of human cytomegalovirus in whole blood. (2011) (21)
Factors associated with a strictly undetectable viral load in HIV‐1‐infected patients (2012) (21)
Use of two real‐time polymerase chain reactions (PCRs) to detect herpes simplex type 1 and 2‐DNA after automated extraction of nucleic acid (2004) (20)
Validation of an automated real-time PCR protocol for detection and quantitation of HIV and HCV genomes in semen. (2006) (20)
Evolution of HIV-1 quasispecies and coreceptor use in cell reservoirs of patients on suppressive antiretroviral therapy. (2014) (20)
Determining the source of nosocomial transmission in hemodialysis units in Tunisia by sequencing NS5B and E2 sequences of HCV (2007) (20)
Evaluation of two RT-PCR screening assays for identifying SARS-CoV-2 variants (2021) (20)
Comparison of two highly automated DNA extraction systems for quantifying Epstein-Barr virus in whole blood. (2008) (20)
Genetic heterogeneity of the envelope 2 gene and eradication of hepatitis C virus after a second course of interferon‐α (2002) (20)
Full-length genome sequences of hepatitis C virus subtype 4f. (2007) (20)
Zidovudine Genotypic Resistance in HIV‐1‐Infected Newborns in the French Perinatal Cohort (2001) (20)
Hepatitis E virus–associated cryoglobulinemia in solid‐organ–transplant recipients (2018) (20)
Hepatitis E virus infection (2013) (20)
Transmission of HCV NS5A Inhibitor-Resistant Variants Among HIV-Infected Men Who Have Sex With Men. (2016) (20)
Study of hepatitis E virus ORF2 antigen kinetics in human-liver chimeric mice and its impact on HEV diagnosis. (2019) (19)
Pre‐emptive intravenous ganciclovir versus valganciclovir prophylaxis for de novo cytomegalovirus‐seropositive kidney‐transplant recipients (2010) (19)
Induction therapy with either anti‐CD25 monoclonal antibodies or rabbit antithymocyte globulins in liver transplantation for hepatitis C (2005) (19)
Comparative effects of mRNA vaccine booster and natural Omicron infection on the neutralizing antibody response (2022) (19)
Multirecombinant Enterovirus A71 Subgenogroup C1 Isolates Associated with Neurologic Disease, France, 2016–2017 (2019) (19)
Does chronic hepatitis E virus infection exist in immunocompetent patients? (2014) (19)
Naturally occurring substitutions conferring resistance to hepatitis C virus polymerase inhibitors in treatment-naive patients infected with genotypes 1–5 (2008) (18)
Screening, diagnosis and risks associated with Hepatitis E virus infection (2019) (18)
Performance of a new rapid test for detecting anti-hepatitis E virus immunoglobulin M in immunocompetent and immunocompromised patients. (2015) (18)
Detection of Zika, dengue and chikungunya viruses using single-reaction multiplex real-time RT-PCR. (2018) (18)
Influence of HCV genotype 1 subtypes on the virus response to PEG interferon alpha‐2a plus ribavirin therapy (2011) (18)
Classification of the Zoonotic Hepatitis E Virus Genotype 3 Into Distinct Subgenotypes (2021) (18)
HEV and transfusion-recipient risk. (2017) (17)
Evolutionary history of hepatitis C virus genotype 5a in France, a multicenter ANRS study. (2011) (17)
HIV-1 genotypic resistance testing using the Vela automated next-generation sequencing platform (2018) (17)
Long-term impact of superinfection by hepatitis G virus in hepatitis C virus-positive renal transplant patients. (1999) (17)
Detection and quantitation of HCV RNA using real‐time PCR after automated sample processing (2007) (17)
Virological Diagnosis of Central Nervous System Infections by Use of PCR Coupled with Mass Spectrometry Analysis of Cerebrospinal Fluid Samples (2013) (17)
Hepatitis E virus. (2013) (16)
Lack of evidence for ribavirin monotherapy efficacy on liver fibrosis in hepatitis C virus positive renal transplant patients. (2005) (16)
Evaluation of a polymerase chain reaction–electrospray ionization time-of-flight mass spectrometry for the detection and subtyping of influenza viruses in respiratory specimens (2013) (16)
Chikungunya in the Caribbean—Threat for Europe (2014) (16)
Brief Report: First Molecular Characterization of HIV‐1 Tunisian Strains (2001) (16)
Ribavirin and abacavir drug interaction in HIV–HCV coinfected patients: fact or fiction? (2012) (16)
Protection of healthcare workers against SARS-CoV-2 reinfection. (2021) (16)
Improved V3 genotyping with duplicate PCR amplification for determining HIV-1 tropism. (2011) (16)
Evaluation of Three Quantitative Anti-SARS-CoV-2 Antibody Immunoassays (2021) (16)
Characterization of CXCR4-using HIV-1 during primary infection by ultra-deep pyrosequencing. (2013) (16)
Liver histology in renal transplant patients after more than 10 years of hepatitis C virus infection. (1996) (16)
Treatment of chronic hepatitis C with recombinant alpha 2b interferon in kidney transplant recipients: preliminary results and side effects. (1995) (16)
[HEV and transfusion-recipient risk]. (2018) (15)
Twenty‐four hour kinetics of hepatitis C virus and antiviral effect of alpha‐interferon (2006) (15)
HIV-1 Dynamics and Coreceptor Usage in Maraviroc-Treated Patients with Ongoing Replication (2012) (15)
Hepatitis E in Transplantation (2016) (15)
Prevalence of antibodies to hepatitis C virus and correlation with liver disease in renal transplant patients. (1997) (15)
Expertise of French Laboratories in Detection, Genotyping, and Quantification of Hepatitis C Virus RNA in Serum (2004) (15)
Treatment of hepatitis C virus infection after kidney transplantation. (2012) (15)
Chronic hepatitis E virus infection in a cirrhotic patient (2017) (15)
Once-daily administration of didanosine in combination with stavudine in antiretroviral-naive patients. The STADI Group. (1999) (14)
Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C Virus Infection in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2018 Clinical Practice Guideline (2019) (14)
Influence of SARS-CoV-2 Variant B.1.1.7, Vaccination, and Public Health Measures on the Spread of SARS-CoV-2 (2021) (14)
Transfusion‐acquired hepatitis E infection misdiagnosed as severe critical illness polyneuromyopathy in a heart transplant patient (2017) (14)
One year later: SARS-CoV-2 immune response and vaccination of healthcare workers post-infection (2021) (14)
Prophylaxis versus pre‐emptive treatment for prevention of cytomegalovirus infection in CMV‐seropositive orthotopic liver‐transplant recipients (2015) (14)
Hepatitis C virus infection in nephrology patients. (2013) (14)
A Follow-Up of the Multicenter Collaborative Study on HIV-1 Drug Resistance and Tropism Testing Using 454 Ultra Deep Pyrosequencing (2016) (14)
Does HEV‐3 subtype play a role in the severity of acute hepatitis E? (2019) (14)
Effect of Zidovudine Resistance Mutations on Virologic Response to Treatment With Zidovudine or Stavudine, Each in Combination With Lamivudine and Indinavir (2002) (14)
Protection of Healthcare Workers Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Reinfection (2021) (14)
Occult hepatitis C virus infection in hemodialysis patients: examining the evidence. (2009) (14)
Four days a week or less on appropriate anti‐HIV drug combinations provided long‐term optimal maintenance in 94 patients: the ICCARRE project (2015) (14)
Resistance mutations in SARS-CoV-2 omicron variant in patients treated with sotrovimab (2022) (14)
High Cure Rate With 24 Weeks of Daclatasvir-Based Quadruple Therapy in Treatment-Experienced, Null-Responder Patients With HIV/Hepatitis C Virus Genotype 1/4 Coinfection: The ANRS HC30 QUADRIH Study. (2015) (14)
Transmission of Hepatitis E Virus With Plasma Exchange in Kidney Transplant Recipients: A Retrospective Cohort Study (2018) (13)
Determination of HCV Genotype Using Two Antibody Assays and Genome Typing (2001) (13)
Clinical performance of a rapid test compared to a microplate test to detect total anti SARS-CoV-2 antibodies directed to the spike protein (2020) (13)
Primary resistance of CCR5-tropic HIV-1 to maraviroc cannot be predicted by the V3 sequence. (2013) (13)
Efficacy and safety of induction therapy with rabbit antithymocyte globulins in liver transplantation for hepatitis C. (2004) (13)
[Hepatitis E virus: Blood transfusion implications]. (2014) (13)
Assessment of a standardized reverse-transcriptase PCR assay for quantifying HIV-1 RNA in plasma and serum. (1996) (13)
Performance of a rapid molecular multiplex assay for the detection of influenza and picornaviruses (2012) (13)
Impact of donor BK polyomavirus replication on recipient infections in living donor transplantation (2018) (13)
Optimized Hepatitis E Virus (HEV) Culture and Its Application to Measurements of HEV Infectivity (2020) (13)
Serological markers of autoimmunity in renal transplant patients before and after alpha-interferon therapy for chronic hepatitis C. (1996) (13)
Lessons from a multicentre study of the detectability of viral genomes based on a two-round quality control of GB virus C (GBV-C)/hepatitis G virus (HGV) polymerase chain reaction assay. (2000) (13)
Association of antiphospholipid syndrome and chronic hepatitis C. (1998) (12)
Hepatitis E virus‐specific T‐cell response after transplantation (2012) (12)
A European multicientre study on the comparison of HBV viral loads between VERIS HBV assay and Roche COBAS® TAQMAN® HBV test, Abbott RealTime HBV assay, Siemens VERSANT HBV assay, and Qiagen artus HBV RG kit. (2017) (12)
Mathematical modeling of hepatitis C virus transmission in hemodialysis. (2009) (12)
A survival method to estimate the time to occurrence of mutations: an application to thymidine analogue mutations in HIV-1-infected patients. (2004) (12)
Does cyclosporine have a beneficial effect on the course of chronic hepatitis C infection after renal transplantation? (2006) (12)
Emerging Mutations and Associated Factors in Patients Displaying Treatment Failure on An Etravirine-Containing Regimen (2012) (12)
Predictive Factors for Humoral Response After 2-dose SARS-CoV-2 Vaccine in Solid Organ Transplant Patients (2021) (12)
Serological Markers of Autoimmunity in Renal Transplant Patients with Chronic Hepatitis C (1998) (12)
Pegylated Interferon-a for Treating Chronic Hepatitis E Virus Infection after Liver Transplantation (2010) (12)
[Hepatitis E virus: an emerging disease]. (2006) (12)
Heterologous ChAdOx1-S/BNT162b2 vaccination: neutralizing antibody response to SARS-CoV-2 (2021) (12)
Multicenter Trials Need To Use the Same Assay for Hepatitis C Virus Viral Load Determination (2007) (12)
Impact of Human Immunodeficiency Virus Type 1 Minority Variants on the Virus Response to a Rilpivirine-Based First-line Regimen (2018) (11)
Analytical sensitivity of three real-time PCR assays for measuring subtype B HIV-1 RNA. (2013) (11)
Detection and quantification of HIV-1 RNA with a fully automated transcription-mediated-amplification assay. (2016) (11)
Prostate‐specific antigen in acute hepatitis and hepatocellular carcinoma (1999) (11)
A 3-month course of ciprofloxacin does not prevent BK virus replication in heavily immunosuppressed kidney-transplant patients. (2016) (11)
Stable prevalence of transmitted drug resistance mutations and increased circulation of non-B subtypes in antiretroviral-naive chronically HIV-infected patients in 2015/2016 in France (2019) (11)
Hydroxychloroquine in COVID-19 patients: what still needs to be known about the kinetics (2020) (11)
Performance comparison of next-generation sequencing platforms for determining HIV-1 coreceptor use (2017) (11)
Viral load and clinical manifestations of hepatitis E virus genotype 3 infections (2019) (11)
Prevalence of complete resistance to at least two classes of antiretroviral drugs in treated HIV‐1‐infected patients: A French nationwide study (2005) (11)
Pilot study of interferon‐α–ribavirin–interleukin‐2 for treatment of nonresponder patients with severe liver disease infected by hepatitis C virus genotype 1 (2006) (11)
An Association between BK Virus Replication in Bone Marrow and Cytopenia in Kidney-Transplant Recipients (2014) (10)
Side effect of a 6 p.m curfew for preventing the spread of SARS-CoV-2: A modeling study from Toulouse, France (2021) (10)
Effector memory CD8 T cell response elicits Hepatitis E Virus genotype 3 pathogenesis in the elderly (2021) (10)
Performance characteristics of the VIDAS® ANTI-HEV IgM and IgG assays. (2019) (10)
Zidovudine genotypic resistance in HIV-1-infected newborns in the French perinatal cohort. (2001) (10)
Evidence of co-infections during Delta and Omicron SARS-CoV-2 variants co-circulation through prospective screening and sequencing (2022) (10)
Influence of vaccination and prior immunity on the dynamics of Omicron BA.1 and BA.2 sub-variants (2022) (10)
Prediction of SARS-CoV-2 Variant Lineages Using the S1-Encoding Region Sequence Obtained by PacBio Single-Molecule Real-Time Sequencing (2021) (10)
Performance evaluation of the Vela Dx Sentosa next-generation sequencing system for HIV-1 DNA genotypic resistance. (2019) (10)
Interpretation of Real-Time PCR Results for Hepatitis C Virus RNA When Viral Load Is Below Quantification Limits (2011) (10)
Patterns of residual HIV-1 RNA shedding in the seminal plasma of patients on effective antiretroviral therapy (2017) (10)
Failure to respond to ribavirin despite elevated intra‐erythrocyte zinc level in transplant‐patients with chronic hepatitis E virus infection (2019) (10)
Shift in phenotypic susceptibility suggests a competition mechanism in a case of acquired resistance to maraviroc. (2010) (10)
Influence of the Delta Variant and Vaccination on the SARS-CoV-2 Viral Load (2022) (10)
Pegylation of IFN-α and Antiviral Activity (2006) (10)
Antiviral Effect of Maraviroc in Semen: A Case Report (2012) (10)
Epidemiology of HCV infection: disease and renal transplantation. (1996) (10)
Children are protected against SARS-CoV-2 infection (2020) (9)
Presence of Lamivudine or Emtricitabine Is Associated with Reduced Emergence of Nonnucleoside Reverse Transcriptase Inhibitor Mutations in an Efavirenz-Based Intermittent Antiretroviral Treatment Regimen (2011) (9)
Prospective evaluation of a new automated nucleic acid extraction system using routine clinical respiratory specimens† (2012) (9)
Apolipoprotein H expression is associated with IL28B genotype and viral clearance in hepatitis C virus infection. (2014) (9)
Virological and immunological effects of salvage therapy following treatment interruption and a shift in HIV‐1 resistance genotype (2002) (9)
Kinetics of HCV Viremia in Kidney Transplant Recipients During and After α-lnterf eron Therapy (1997) (9)
Novel T cell interferon gamma release assay (IGRA) using spike recombinant protein for COVID19 vaccine response and Nucleocapsid for SARS-Cov2 response (2022) (9)
[HCV RNA clearance after treatment with interferon-alpha in chronic hemodialysis patients with or without coinfection by HGV/HGBV-C]. (1997) (9)
HCV-Related Mortality Among HIV/HCV Co-infected Patients: The Importance of Behaviors in the HCV Cure Era (ANRS CO13 HEPAVIH Cohort) (2019) (9)
Hepatitis E Virus: How It Escapes Host Innate Immunity (2020) (9)
Quantifying the impact of public health protection measures on the spread of SARS-CoV-2 (2020) (9)
Laboratory evaluation of the UniCel DxI 800 analyser (Beckman Coulter) for detecting HBV and HCV serological markers. (2009) (9)
Antibody Titers and Protection against Omicron (BA.1 and BA.2) SARS-CoV-2 Infection (2022) (9)
COVID‐19 pandemic period, where are the seasonal viruses? (2021) (8)
A fully automated system using transcription-mediated amplification for the molecular diagnosis of hepatitis E virus in human blood and faeces. (2018) (8)
[Hepatitis C virus reinfection after an intravenous drug injection]. (1998) (8)
[Chronic hepatitis E virus infection]. (2009) (8)
Position-specific automated processing of V3 env ultra-deep pyrosequencing data for predicting HIV-1 tropism (2015) (8)
Increased CXCR3+ T Cells Impairs Recruitment of T-Helper Type 17 Cells via Interferon γ and Interleukin 18 in the Small Intestine Mucosa During Treated HIV-1 Infection (2019) (8)
Seroprevalence of hepatitis E virus among blood donors on Corsica, France, 2017 (2020) (8)
Evaluation of two VIDAS ®prototypes for detecting anti-HEV IgG. (2017) (8)
HIV-1-Resistant Strains during 8-Week on 8-Week off Intermittent Therapy and their Effect on CD4+ T-cell Counts and Antiviral Response (2008) (8)
Post-vaccination SARS-CoV-2 antibody kinetics and protection duration (2021) (8)
A new generation of serum anti-HIV antibody immunocapture assay for saliva testing. (1997) (8)
Genetic heterogeneity of the NS5A gene of hepatitis C virus and early response to interferon-alpha. (2003) (8)
[Cytomegalovirus effects in solid organ transplantation and the role of antiviral prophylaxis]. (2010) (8)
Intra-host viral variability in children clinically infected with H1N1 (2009) pandemic influenza. (2015) (8)
Evolution of hepatitis C virus quasispecies in renal transplant patients with de novo glomerulonephritis (2003) (8)
Oxford-AstraZeneca COVID-19 vaccine-induced cerebral venous thrombosis and thrombocytopaenia: A missed opportunity for a rapid return of experience (2021) (8)
Analytical performance of the VERIS MDx system HCV assay for detecting and quantifying HCV RNA. (2016) (8)
[Hepatitis E: from zoonotic transmission to chronic infection in immunosuppressed patients]. (2008) (8)
Peripheral Plasma and Semen Cytokine Response to Zika Virus in Humans (2019) (8)
Treatment of Chronic Hepatitis C Virus Infection in Dialysis Patients: An Update (2010) (8)
Mechanisms of HIV-1 evasion to the antiviral activity of chemokine CXCL12 indicate potential links with pathogenesis (2021) (8)
Comparison of Cobas® HPV and Anyplex™ II HPV28 assays for detecting and genotyping human papillomavirus. (2017) (7)
Parsonage-Turner syndrome due to autochthonous acute genotype 3f hepatitis E virus infection in a nonimmunocompromised 55-year-old patient (2017) (7)
Estimating the impact of public health strategies on the spread of SARS‐CoV‐2: Epidemiological modelling for Toulouse, France (2021) (7)
Association between genes of the major histocompatibility complex class II and the outcome of hepatitis C virus infection. (1999) (7)
Hepatitis E Virus Infections among Patients with Acute Febrile Jaundice in Burkina Faso (2019) (7)
Pegylation of IFN-alpha and antiviral activity. (2006) (7)
The influence of the nasopharyngeal viral load on the spread of the Omicron BA.2 variant. (2022) (7)
Follow-up of 28 HCMV seropositive renal-transplant recipients: comparison of clinical, biological and virological parameters in the groups of treated versus untreated infected patients. (2004) (7)
X4 Tropic Multi-Drug Resistant Quasi-Species Detected at the Time of Primary HIV-1 Infection Remain Exclusive or at Least Dominant Far from PHI (2011) (7)
A severe monkeypox infection in a patient with an advanced HIV infection treated with tecovirimat: clinical and virological outcome (2022) (7)
Decrease of Lewis frequency in HIV-infected patients: possible competition of fucosylated antigens with HIV for binding to DC-SIGN (2005) (7)
Virological failure of patients on maraviroc-based antiretroviral therapy. (2015) (7)
Brief Report: HIV-1 Tropism During Primary Infections in France 1996–2014 (2016) (7)
HIV therapy after treatment interruption in patients with multiple failure and more than 200 CD4+ T lymphocyte count (2004) (7)
Boceprevir-Based Triple Antiviral Therapy for Chronic Hepatitis C Virus Infection in Kidney-Transplant Candidates (2015) (7)
Retreatment with direct-acting antivirals of genotypes 1-3-4 hepatitis C patients who failed an anti-NS5A regimen in real world. (2017) (7)
Hepatitis E prevalence in French Polynesian blood donors (2018) (7)
Convenient Biological Assay for Polyethylene Glycol-Interferons in Patients with Hepatitis C (2004) (7)
Ribavirin for Chronic Hepatitis E Virus Infection in Ibrutinib-Exposed Patients (2019) (7)
Performance of a completely automated system for monitoring CMV DNA in plasma. (2016) (6)
Plasma Hepatitis E Virus Kinetics in Solid Organ Transplant Patients Receiving Ribavirin (2019) (6)
A European multicientre study on the comparison of HIV-1 viral loads between VERIS HIV-1 Assay and Roche COBAS® TAQMAN® HIV-1 test, Abbott RealTime HIV-1 Assay, and Siemens VERSANT HIV-1 Assay. (2017) (6)
Humoral and Cellular Immune Responses of Solid Organ Transplant Patients on Belatacept to Three Doses of mRNA-Based Anti-SARS-CoV-2 Vaccine (2022) (6)
Testing individual and pooled saliva samples for sars-cov-2 nucleic acid: a prospective study (2021) (6)
Risk for Hepatitis E Virus Transmission by Solvent/Detergent–Treated Plasma (2020) (6)
Analyses of Clinical and Biological Data for French and Belgian Immunocompetent Patients Infected With Hepatitis E Virus Genotypes 4 and 3 (2021) (6)
When Should Ribavirin Be Started to Treat Hepatitis E Virus Infection in Transplant Patients? (2016) (6)
Sperm Washing and Virus Nucleic Acid Detection to Reduce HIV and HCV Transmission in Serodiscordant Couples (Male Partner Infected) Wishing Children (2000) (6)
Addition of Maraviroc Versus Placebo to Standard Antiretroviral Therapy for Initial Treatment of Advanced HIV Infection (2020) (6)
[Hepatitis C infection among patients receiving hemodialysis]. (2003) (6)
Safety measures to prevent hepatitis E virus transmission by blood transfusion (2014) (5)
In vitro mitogen-stimulated T-cell from hepatitis C virus-positive liver transplantation candidates, increases T-cell activation markers and T-cell proliferation. (2008) (5)
Atypical hemolytic uremic syndrome triggered by varicella infection (2017) (5)
Virological exploration of individuals with discordant HIV screening tests. (2004) (5)
Linked transmission chains of imported SARS-CoV-2 variant B.1.351 across mainland France, January 2021 (2021) (5)
Hepatitis E Virus Infection: Neurological Manifestations and Pathophysiology (2021) (5)
Performance comparison of deep sequencing platforms for detecting HIV‐1 variants in the pol gene (2018) (5)
Determining the therapeutic range for ribavirin in transplant recipients with chronic hepatitis E virus infection (2020) (5)
Human Cytomegalovirus Infection Changes the Pattern of Surface Markers of Small Extracellular Vesicles Isolated From First Trimester Placental Long-Term Histocultures (2021) (5)
Intrahepatic cytokine profile in renal‐transplant patients infected by hepatitis C virus (2005) (5)
A European multicentre study on the comparison of HCV viral loads between VERIS HCV assay and COBAS® TaqMan® HCV Test and RealTime HCV Assay. (2017) (5)
Evaluation of the QIAsymphony™ SP and Artus™ RealTime extraction-quantification systems for measuring HIV-1 virus load. (2011) (5)
Performance of a commercial assay for detecting and quantifying HEV RNA in faeces (2018) (5)
Adaptive lymphocyte profile analysis discriminates mild and severe forms of COVID-19 after solid organ transplantation (2021) (5)
A new highly automated extraction system for quantitative real-time PCRs from whole blood samples: routine monitoring of opportunistic infections in immunosuppressed patients. (2012) (5)
Clinical performance of the LCx HCV RNA quantitative assay. (2005) (5)
Viral load and mother-to-infant HIV transmission (1992) (5)
Screening for Hepatitis B Virus DNA in Serum of Organ Donors and Renal Transplant Recipients (2003) (5)
No evidence of occult hepatitis C or E virus infections in liver‐transplant patients with sustained virological response after therapy with direct acting agents (2019) (5)
Identification of a duplicated V3 domain in NS5A associated with cirrhosis and hepatocellular carcinoma in HCV-1b patients. (2015) (5)
Antiviral and Anti-Inflammatory Activities of Fluoxetine in a SARS-CoV-2 Infection Mouse Model (2022) (5)
European Multicenter Study on Analytical Performance of DxN Veris System HCV Assay (2017) (5)
Evolution of Hepatitis C Virus Quasispecies during Therapy with Il2 Combinated to Alpha Interferon and Ribavirin (2005) (5)
Mobilization of γδ T Cells and IL-10 Production at the Acute Phase of Hepatitis E Virus Infection in Cytomegalovirus Carriers (2021) (4)
Kinetics of HCV viremia in kidney transplant recipients during and after alpha-interferon therapy. (1997) (4)
Omicron breakthrough infection in a kidney‐transplant patient given pre‐exposition casirivimab and imdevimab monoclonal antibodies (2022) (4)
Casirivimab-Imdevimab to Prevent SARS-CoV-2 Infections in Solid Organ Transplant Recipients. (2022) (4)
No evidence of sexual transmission of HEV among individuals using HIV pre‐exposure prophylaxis (2020) (4)
Th22 cells are efficiently recruited in the gut by CCL28 as an alternative to CCL20 but do not compensate for the loss of Th17 cells in treated HIV-1-infected individuals (2020) (4)
Influence of pre-analytical conditions on plasma ribavirin concentrations (2010) (4)
Should 12‐ or 24‐week post‐ribavirin follow‐up be considered to define sustained virological response in transplant patients treated for chronic hepatitis E virus infection? (2019) (4)
Ultrasensitive Human Immunodeficiency Virus Type 1 Viral Load as a Marker of Treatment Choice for Simplification Strategies (2018) (4)
THETA: a new genotypic approach for predicting HIV-1 CRF02-AG coreceptor usage (2019) (4)
Decreased Efficiency of Neutralizing Antibodies from Previously Infected or Vaccinated Individuals against the B.1.617.2 (Delta) SARS-CoV-2 Variant (2022) (4)
Algorithm-Based Prediction of HIV-1 Subtype D Coreceptor Use (2013) (4)
HIV-1-infected patients from the French National Observatory experiencing virological failure while receiving enfuvirtide. (2008) (4)
Human Cytomegalovirus Modifies Placental Small Extracellular Vesicle Composition to Enhance Infection of Fetal Neural Cells In Vitro (2022) (4)
Multicenter Quality Control of Hepatitis C Virus Protease Inhibitor Resistance Genotyping (2013) (4)
Baseline and Post-Treatment Hepatitis C NS5A Resistance in Relapsed Patients from a Multicentric Real-Life Cohort (2018) (4)
Treatment of chronic hepatitis B and C with alpha interferon in a renal transplant patient. (1996) (4)
Monitoring human cytomegalovirus (HCMV) in HCMV-seropositive orthotopic liver-transplant recipients by means of quantitative real-time polymerase chain reaction. (2006) (4)
Influence of age on the spread of SARS-CoV-2 variant B.1.1.7 (2021) (4)
[Hepatitis E infection in dialysis and after transplantation]. (2010) (4)
HIV-1 Tropism and Liver Fibrosis in HIV–HCV Co-Infected Patients (2012) (4)
[161] HEPATITIS E VIRUS INFECTION CAN EVOLVE TO CHRONIC HEPATITIS IN ORGAN-TRANSPLANT PATIENTS (2007) (3)
Mise au point d’une technique multiplex de dépistage génomique HEV–HAV (2012) (3)
[Hepatitis B virus resistance]. (2004) (3)
Hepatitis E virus infection and ribavirin treatment in patients with chronic lymphocytic leukemia receiving ibrutinib (2017) (3)
1067 Acute hepatitis E: a study of 17 consecutive patients in South-West France over a 13 month period (2003) (3)
[Hepatitis E virus]. (2015) (3)
[Does a healthy carrier of hepatitis C exist?]. (1996) (3)
Omicron Wave SARS-CoV-2 Diagnosis: Evaluation of Saliva, Anterior Nasal, and Nasopharyngeal Swab Samples (2022) (3)
Analytical performance of VERIS MDx system HBV assay for quantifying HBV DNA (2015) (3)
Clinical phenotype and outcome of hepatitis E virus associated neuralgic amyotrophy; an international retrospective comparative cohort study (2017) (3)
Malignancies in hepatitis C virus‐positive and ‐negative kidney transplant recipients: A case‐controlled study (2017) (3)
No selection of CXCR4-using variants in cell reservoirs of dual-mixed HIV-infected patients on suppressive maraviroc therapy (2016) (3)
Reduced progression of bone erosion in cytomegalovirus seropositive rheumatoid arthritis patients (2020) (3)
Influenza A (H1N1) virus‐induced hepatocellular injury in a kidney transplant patient (2011) (3)
Rat Hepatitis E Virus: Presence in Humans in South-Western France? (2021) (3)
Virus et sperme : implications en assistance médicale à la procréation (2002) (3)
Is the unbound concentration of atazanavir of interest in therapeutic drug monitoring? (2017) (3)
Phenotypic Resistance Pattern of HIV‐1 Isolates With Zidovudine and/or Multidrug Resistance Mutations After Didanosine‐Stavudine Combination Therapy (2000) (3)
Naı̈ve T-Cell Depletion Related to Infection by X 4 Human Immunodeficiency Virus Type 1 in Poor Immunological Responders to Highly Active Antiretroviral Therapy † (2006) (3)
Acute HCV infection detected in a blood donor by NAT (2003) (3)
Culture du virus de l’hépatite C, enfin ! (2007) (3)
Intermittent selection pressure with zidovudine plus zalcitabine treatment reduces the emergence in vivo of zidovudine resistance HIV mutations (1999) (3)
Increase of CXCR3+ T cells impairs Th17 cells recruitment in the small intestine mucosa through IFN-γ and IL-18 during treated HIV-1 infection. (2019) (2)
[Conditions of "thymidine analog mutations" (TAMs) in naive patients treated with different combinations of d4T]. (2000) (2)
Hepatitis C virus infection in French hemodialysis units: A multicenter studyThis work was carried out on behalf of the Multicenter “VHC Hémodialyse” Group. (2000) (2)
Predictive Factors, Natural History and Outcome of Chronic Hepatitis E Virus Infection in Solid-Organ-Transplant Patients: A Retrospective Multicenter Study (2011) (2)
Diagnosis options in patients suffering from COVID‐19‐like symptoms (2020) (2)
Modulation of gene expression in CD4+ T lymphocytes following in vitro HIV infection: a comparison between human and chimpanzee (2015) (2)
L’hépatite virale E (2009) (2)
Highlights from the 2012 International Symposium on HIV & Emerging Infectious Diseases (ISHEID): from cART management to the search of an HIV cure (2012) (2)
Sexual transmission of an extensively drug-resistant HIV-1 strain. (2020) (2)
Hepatitis E Virus Quasispecies in Cerebrospinal Fluid with Neurological Manifestations (2021) (2)
Performance of two commercial assays for detecting HEV (2013) (2)
No evidence of genotype-3 hepatitis E virus-induced myocarditis. (2016) (2)
European Multicenter Study on Analytical Performance of Veris HIV-1 Assay (2017) (2)
Low serum neutralization of Omicron variants a month after AZD7442 prophylaxis initiation (2022) (2)
Impact of the mutational load on the virological response to a first-line rilpivirine-based regimen (2018) (2)
Glucocorticoid use as a cause of non-cellular immune response to SARS-Cov2 Spike in patients with immune system diseases (2022) (2)
A European multicenter study on the analytical performance of the VERIS HBV assay. (2018) (2)
[Hepatitis C virus infection in renal-transplant patients]. (2004) (2)
Impact of Casirivimab-Imdevimab on Severe Acute Respiratory Syndrome Coronavirus 2 Delta Variant Nasopharyngeal Virus Load and Spike Quasispecies (2022) (2)
The Prevalence of Hepatitis E in a Patient Cohort Presenting With Addictive Injection Behavior (2019) (2)
[Hepatitis E: an emerging disease]. (2012) (2)
Long-term evolution of transmitted CXCR4-using HIV-1 under effective antiretroviral therapy. (2019) (2)
Should Persistent Hepatitis E Virus Replication in Transplant Patients Be Tolerated? (2017) (2)
The real seroprevalence of SARS-CoV-2 in France and its consequences for virus dynamics (2020) (2)
Four days a week and less on appropriate antiviral combinations provided long-term optimal control over HIV-1 in 92 patients (2014) (2)
Une hépatite émergente : l’hépatite E (2006) (2)
[HCV nosocomial infections in hemodialysis]. (2001) (1)
What are the Management Issues for Hepatitis C in Dialysis Patients? (2014) (1)
153 Acute hepato-cellular failure with encephalopathy in French patients with autochthonous acute sporadic hepatitis E (2006) (1)
Increased risk of severe COVID-19 in hospitalized patients with SARS-CoV-2 Alpha variant infection: a multicentre matched cohort study (2022) (1)
[Hepatitis C following kidney transplantation]. (1998) (1)
315 HEPATITIS E IN HAEMATOLOGY: A RISK OF SEVERE THROMBOCYTOPENIA IN IMMUNOCOMPETENT PATIENTS AND PROLONGED HEPATITIS IN PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES (2010) (1)
EVOLUTION OF THE HYPERVARIABLE REGION-1 OF HEPATITIS C VIRUS AND LIVER FIBROSIS PROGRESSION IN RENAL-TRANSPLANT RECIPIENTS (2004) (1)
[Longitudinal evaluation of lymphocyte subsets and serum immunoglobulins in infants born to HIV seropositive mothers]. (1993) (1)
Strong SARS-CoV-2-neutralizing antibody response of previously-infected healthcare workers given one dose of mRNA vaccine. (2021) (1)
Maraviroc/raltegravir simplification strategy following 6 months of quadruple therapy with tenofovir/emtricitabine/maraviroc/raltegravir in treatment-naive HIV patients. (2016) (1)
Primary resistance of CCR 5-tropic HIV-1 to maraviroc cannot be predicted by the V 3 sequence (2013) (1)
[Acute hepatitis during pregnancy: hepatitis E virus must be considered]. (2005) (1)
Clinical Course and Risk Factors for severe Disease and Death of Adult Critically Ill Inpatients with COVID-19 in Toulouse, France: A Retrospective Cohort Study (2020) (1)
High SARS-CoV-2 IgG seroprevalence among pregnant Cameroun women 14 months after the beginning of the pandemic (2022) (1)
[Is there a place for ribavirin in the treatment for renal transplant patients infected by hepatitis C virus?]. (2003) (1)
Diagnostic Performance of an Automated System for Assaying Anti-Hepatitis E Virus Immunoglobulins M and G Compared with a Conventional Microplate Assay (2022) (1)
Persistent But Not Replicating HIV-1 Cell-Associated DNA in Semen of Long-Term ART Experienced Men. (2016) (1)
[Development of a multiplex technique for detecting simultaneously HAV RNA and HEV RNA]. (2012) (1)
[Eradication of hepatitis C virus after 3 months of interferon and ribavirin treatment in an a interferon non-responder patient with chronic hepatitis C]. (2001) (1)
[Long-term consequences of co-infection by hepatitis G virus in hepatitis c virus infected kidney transplant patients]. (1999) (1)
Seven years (2015-2021) of blood donor screening for HEV-RNA in France: lessons and perspectives. (2022) (1)
A Non-Human Enterovirus A71 Brainstem Encephalitis in France In 2016 (2017) (1)
Comment on: High sensitivity of specific genotypic tools for detection of X4 variants in antiretroviral-experienced patients suitable to be treated with CCR5 antagonists. (2010) (1)
[Prevalence and incidence of hepatitis C virus in hemodialysis: diagnosis and prevention]. (2008) (1)
A simple, sensitive and quantitative FACS-based test for SARS-CoV-2 serology in humans and animals (2021) (1)
P0621 : Hepatitis E virus in patients with decompensated chronic liver disease and alcoholic hepatitis: A UK/French study (2015) (1)
HIV-1 escape in the central nervous system on elvitegravir-based antiretroviral therapy. (2019) (1)
Blood by Real-Time PCR Assay Human Cytomegalovirus DNA in Whole Automated Extraction and Quantification of (2003) (1)
Title HIV-1 Tat Protein Induces PD-L 1 ( B 7-H 1 ) Expression on Dendritic Cells through Tumor Necrosis Factor Alpha-and Toll-Like Receptor 4-Mediated Mechanisms Permalink (2014) (1)
Whole‐genome sequencing of SARS‐CoV‐2: Comparison of target capture and amplicon single molecule real‐time sequencing protocols (2022) (1)
Hepatitis E virus infection and acute non-traumatic neurological injury: an international prospective pilot study (2017) (1)
Accurate quantification of CXCR4-using HIV-1 variants by Illumina deep-sequencing (2018) (1)
Occult Hepatitis C Virus Infection: Where are We Now? (2011) (1)
Th22 cells are efficiently recruited in the gut by CCL28 as an alternative to CCL20 but do not compensate for the loss of Th17 cells in treated HIV-1-infected individuals (2020) (1)
Natural non-homologous recombination led to the emergence of a duplicated V3-NS5A region in HCV-1b strains associated with hepatocellular carcinoma (2017) (1)
36 – Hepatitis E (2018) (1)
The mechanisms underlying the immune control of Zika virus infection at the maternal-fetal interface (2022) (1)
Unmet Needs for the Treatment of Chronic Hepatitis E Virus Infection in Immunocompromised Patients (2022) (1)
[Originality of entry inhibitors]. (2009) (0)
[A new system for the culture of hepatitis C virus]. (2007) (0)
334 HC07 ANRS trial - pilot study of triple therapy by recombinant interferona2A- ribavirin- IL-2 for treatment of nonresponder patients with severe liver disease infected by hepatitis C virus (HCV) genotype 1 (2003) (0)
Human cytomegalovirus infection changes the pattern of surface markers of small extracellular vesicles isolated from first trimester placental histocultures (2020) (0)
PVI-14 NS3 protease polymorphism and resistance profile to protease inhibitors in French patients infected with hepatitis C virus (HCV) genotypes 1 to 5 (2009) (0)
Glucocorticoids selectively affect the memory T cell response to SARS-Cov2 spike in vaccinated and post-infected patients with systemic lupus erythematosus (2023) (0)
HIV-1 resistance genotyping by ultra-deep sequencing and 6-month virological response to first-line treatment. (2022) (0)
Automated sample extraction for quantitative HCV RNA testing: towards full automation of viral load testing (2001) (0)
Eleventh International Congress on Drug Therapy in HIV Infection (2012) (0)
796 FACTORS ASSOCIATED WITH SUSTAINED VIROLOGICAL RESPONSE IN HCV/HIV PATIENTS RETREATED WITH PEG-INTERFERON-a2a-360 μg/wk AND RIBAVIRIN HIGH DOSE: RESULTS OF THE ANRS-HC-20 ETOC STUDY (2013) (0)
Hepatitis E: The Commonest Viral Zoonosis Worldwide? (2015) (0)
Author's response to reviews Title: The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): Early findings, 2006-2010 Authors: Marc-Arthur (2010) (0)
Vectorial Release of Human RNA Viruses from Epithelial Cells (2022) (0)
564 TREATMENT OF AUTOCHTHONOUS ACUTE HEPATITIS E IN IMMUNOCOMPETENT PATIENTS WITH SHORT TERM RIBAVIRIN: A MULTICENTRIC FRENCH EXPERIENCE (2012) (0)
Diagnostic and management strategies for chronic hepatitis E infection (2023) (0)
Subtype D Coreceptor Use Algorithm-Based Prediction of HIV-1 (2014) (0)
Effect of hepatitis E virus infection on the human hepatic innate immune response in human liver chimeric mice (2016) (0)
Impact of previous exposure to systemic corticosteroids on unfavorable outcome in patients hospitalized for COVID-19 (2021) (0)
Evaluation of the H-DiaCMVQ kit® for detecting and quantifying CMV-DNA in plasma and in whole blood samples (2016) (0)
P693 NEUROLOGIC DISORDERS DURING HEV INFECTION IN NONIMMUNOCOMPROMISED PATIENTS (2014) (0)
129 PREDICTIVE FACTORS, NATURAL HISTORY AND OUTCOME OF CHRONIC HEPATITIS E VIRUS INFECTION IN SOLID-ORGAN-TRANSPLANT PATIENTS: A RETROSPECTIVE MULTICENTER STUDY (2011) (0)
[8th international symposium "Alain Feuillu" - Emergency biology and blood gases]. (2021) (0)
Modulation of gene expression in CD4+ T lymphocytes following in vitro HIV infection: a comparison between human and chimpanzee (2015) (0)
Virus and semen: implication in assisted medical procreation (2002) (0)
CLINICAL—LIVER, PANCREAS, AND BILIARY TRACT Ribavirin Therapy Inhibits Viral Replication on Patients With Chronic Hepatitis E Virus Infection (2010) (0)
Performance evaluation of new automated VIDAS anti-HEV immunoassay tests (2018) (0)
HEPATITIS C VIRUS INFECTION IN NEPHROLOGY PATIENTS ÃÅÏÀÒÈÒ Ñ-ÂÈÐÓÑÍÀß ÈÍÔÅÊÖÈß Ó ÍÅÔÐÎËÎÃÈ×ÅÑÊÈÕ ÏÀÖÈÅÍÒÎÂ (2013) (0)
Le génotype 5 du virus de l’hépatite C (2005) (0)
Can the COVID-19 Pandemic Improve the Management of Solid Organ Transplant Recipients? (2022) (0)
Hepatitis E virus: from the infected organism to the cellular response. (2018) (0)
P79 Hepatitis E virus is highly endemic in South West France (2010) (0)
[Genotypic recombination and hepatitis C virus]. (2008) (0)
Phenotypic resistance pattern of HIV-1 isolates with zidovudine and/or multidrug resistance mutations after didanosine-stavudine combination therapy. (2000) (0)
Strong Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody Response of Previously Infected Healthcare Workers Given 1 Dose of mRNA Vaccine (2021) (0)
Characterisation of the Specificity, Functionality and Durability of Host T-Cell Responses against the Full HEV Genome (2016) (0)
Hepatitis C Virus Genotyping Using an Oligonucleotide Microarray Based on the NS5B Sequence (cid:1) † (2010) (0)
Toscana virus meningitis in Southwestern France (2016) (0)
Iconography : Hepatitis E is an autochthonous disease in industrialized countries (2008) (0)
[Early hematological consequences in infants born to HIV seropositive mothers treated with zidovudine during pregnancy]. (1995) (0)
Evaluation of the H-DiaCMVQ kit for detecting and quantifying CMD-DNA in whole blood samples (2015) (0)
[Viral hepatitis E]. (2009) (0)
Tipranavir in highly ARV-experienced patients: efficacy and tolerability results from the French prospective NADIS cohort (2008) (0)
Interpretation of Real-Time PCR Results for Hepatitis C Virus RNA When Viral Load Is Below Quantiﬁcation Limits (cid:1) (2011) (0)
Sirolimus in Severe Hyperinsulinemic Hypoglycemia (2014) (0)
802 CHARACTERIZATION OF A MAJOR V3 DUPLICATION IN THE NS5A REGION OF GENOTYPE IB HCV BY QUASISPECIES ANALYSIS IN A FRENCH MULTICENTER STUDY (2011) (0)
A Biliary Milestone: Functional Expression of the Human Bile Salt Export Pump (2002) (0)
Ebola 2014-2015 and SARS-CoV-2 2019-2020: Two distinct situations but similar collateral damage (2020) (0)
Genotype specific pathogenicity of hepatitis E virus at the human maternal-fetal interface (2018) (0)
Low to undetectable Omicron BQ.1.1 neutralization by patient’s sera a month after initiation of AZD7442 600mg (2023) (0)
The pressing need for a global HEV vaccine. (2023) (0)
[Treatment of hepatitis E virus infection]. (2015) (0)
Retreatment with Direct Active Antivirals of genotype 1, 3 and 4 chronic hepatitis C patients who previously failed an anti-NS5A-containing regimen in real world (2017) (0)
[Hepatitis E virus replication in intestinal cells: A new facet of this virus revealed]. (2021) (0)
Consequences of human cytomegalovirus infection on small extracellular vesicles isolated from first trimester placental histocultures (2020) (0)
Humoral and Cellular Responses to a Delayed Fourth SARS-CoV-2 mRNA-Based Vaccine in Weak Responders to 3 Doses Kidney Transplant Recipients (2022) (0)
Consultants for the American Journal of Nephrology 1996 (1996) (0)
A multicentric study on the analytical performance of the DxN Veris MDx System CMV assay (2015) (0)
P187: Co‐ circulation of hepatitis A, B and C with hepatitis E virus genotype 1a during major outbreak of 2014 in Nepal (2015) (0)
Replication Maraviroc-Treated Patients with Ongoing HIV-1 Dynamics and Coreceptor Usage in (2013) (0)
Title HIV-1 Tat protein induces production of proinflammatory cytokines by human dendritic cells and monocytes / macrophages through engagement of TLR 4-MD 2-CD 14 complex and activation of NF-κB pathway (2015) (0)
Replicationd Patients with Ongoing HIV-1 Dynamics and Coreceptor Usage in (2014) (0)
Is long-term chronic immunosuppression therapy detrimental in hepatitis C virus-positive renal transplant patients? (1998) (0)
EFFICACY AND SAFETY OF INDUCTION THERAPY WITH ANTITHYMOCYTE GLOBULINS (ATG) IN HEPATITIS C VIRUS (HCV) POSITIVE LIVER TRANSPLANT PATIENTS : COMPARISON WITH ANTI-CD25 INDUCTION THERAPY (2004) (0)
Evaluation of the Iam CMV Q-LAMP Quantitative assay for detecting and quantifying CMD-DNA in plasma samples (2015) (0)
Chronic hepatitis E virus infection: is it reality or hype and where does it matter? (2020) (0)
[The evolution of the hypervariable region-1 of hepatitis C virus may predict liver fibrosis outcome after renal transplantation]. (2005) (0)
Emerging resistance mutations in PI-naive patients failing an atazanavir-based regimen (ANRS multicentre observational study) (2018) (0)
Whole‐genome single molecule real‐time sequencing of SARS‐CoV‐2 Omicron (2023) (0)
Multiplex technology for the detection of gastrointestinal viruses in stool samples from diarrheic children (2016) (0)
Impact of HEV infection on the human hepatic innate immune response in human liver chimeric mice (2017) (0)
Hepatitis E infection in adults with primary immunodeficiency with or without immunoglobulin replacement therapy. (2022) (0)
IN REPLY TO'EVIDENCE OF OCCULT HEPATITIS C VIRUS INFECTION IN HEMODIALYSIS PATIENTS' (2009) (0)
[Clinical significance of detection and quantification of hepatitis C virus RNA in hemodialysis: proposal for a rational diagnostic strategy]. (1997) (0)
Contents Vol. 16, 1998 (2000) (0)
[Hepatitis E virus infection]. (2018) (0)
Persistence of hepatitis E virus in the cerebrospinal fluid despite apparently successful ribavirin therapy. (2022) (0)
Herpes Simplex 1-2 in broncho alveolar fluid: A 5 years retrospective study (2016) (0)
P188: Hepatitis E IgG seroprevalence in three hyperendemic areas: Nepal, Bangladesh and southwest France (2015) (0)
Elsevier has created a Monkeypox Information Center in response to the declared public health emergency of international concern, with free information in English on the monkeypox virus. The Monkeypox Information (2022) (0)
COVID-19 diagnosis in a Senegalese company: A model for COVID-19 vaccination? (2021) (0)
Will the latest wave of the COVID‐19 pandemic be an ecological disaster? There is an urgent need to replace plastic by ecologically virtuous materials (2022) (0)
7 Human immunodeficiency virus (2012) (0)
Human Cytomegalovirus modifies placental small extracellular vesicle secretion and composition towards a proviral phenotype to enhance infection of fetal recipient cells (2021) (0)
Detection of Hepatitis E Virus in Sewage After an Outbreak on a French Island (2016) (0)
Hepatitis E Virus Seroprevalence and Chronic Infections in Patients with HIV , Switzerland KENFAK-FOGUENA (2019) (0)
Post-vaccination SARS-CoV-2 antibody kinetics and protection duration against Omicron in elderly population (2022) (0)
Management of Hepatitis A and E Virus Infection (2021) (0)
Apolipoprotein-A-I for severe COVID-19-induced hyperinflammatory states: A prospective case study (2022) (0)
27 – Hepatitis E Vaccines (2018) (0)
Global health. People, animals, plants, the environment: towards an integrated approach to health (2019) (0)
Subject Index Vol. 16, 1996 (1996) (0)
A European Multicentric Study on the analytical performance of DxN VERIS MDx system HBV assay (2015) (0)
, Lionel Sebastien Lhomme , Florence Abravanel , Martine Dubois , Immunocompromised Patients of the Hepatitis E Virus in Characterization of the Polyproline Region (2014) (0)
Subtype analysis and mutations to antiviral drugs in HIV-1-infected patients from Mozambique before initiation of antiretroviral therapy: Results from the DREAM programme (p 452-458) (2005) (0)
We must not forget the most disadvantaged people facing the COVID-19 crisis (2020) (0)
Virus Lifecycle and Identification of 3 Forms of the ORF 2 Capsid 2 Protein 3 4 Short title : 5 (2017) (0)
Aminobisphosphonates reveal a selective anti-viral potential of Vγ9Vδ2 T cells (2016) (0)
[HIV risk and procreation, how to reduce HIV and HCV transmission risk for serodiscordant couples?]. (2005) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Jacques Izopet?

Jacques Izopet is affiliated with the following schools:

Federal University of Toulouse Midi-Pyrénées
Université Paris Cité